SavedAdd your journal

Journals / Osmangazi Tıp Dergisi / 2017 / Cilt: 39 - Sayı: 3

Growth Hormone Treatment Indications in Children and Adolescents

Çocuk ve Ergenlerde Büyüme Hormonu Tedavisi Endikasyonları

ENVER ŞİMŞEK
TÜLAY ŞİMŞEK
Pages
104–114
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this manuscript, we summarize the growth hormone treatment indications among pediatric and transition patients

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Until 1985 growth hormone (GH) was obtained from pituitary extracts, and was available in limited amounts only to treat severe growth hormone deficiency.
📊
Key Findings & Data:Recombinant human GH has replaced human pituitary-derived GH, which should no longer be used because of the risk of contamination with the Jakob Creutzfeld prion.
💡
Conclusion & Impact:In this manuscript, we summarize the growth hormone treatment indications among pediatric and transition patients
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Until 1985 growth hormone (GH) was obtained from pituitary extracts, and was available in limited amounts only to treat severe growth hormone deficiency. Recombinant human GH has replaced human pituitary-derived GH, which should no longer be used because of the risk of contamination with the Jakob Creutzfeld prion. Although with some differences between different countries, GH treatment is indicated in children with growth hormone deficiency, Turner syndrome, chronic renal insufficiency, Prader-Willi syndrome, deletions/mutations of the SHOX gene, as well as in short children born small for gestational age and with idiopathic short stature. For pediatric patients, guidelines for the use of GH have been developed by several organizations that have identified specific criteria for initiating GH therapy. In this manuscript, we summarize the growth hormone treatment indications among pediatric and transition patients

Özet

1985 yılına kadar büyüme hormonu hipofiz ekstrelerinden elde ediliyordu ve çok sınırlı sayıda ciddi büyüme hormonu eksikliği (BHE) olan hastalarda kullanılıyordu. Rekombinant DNA teknolojisi ile BH yeterli miktarda üretilmeye başlandıktan sonra çocuklarda büyüme hormonu tedavi endikasyonları genişleyerek, büyüme hormonu eksikliği olmayan hastalıklara bağlı boy kısalıklarında da kullanılmaya başladı. Ülkeler arasında BH tedavi endikasyonları farklılık göstermekle birlikte, BH tedavi endikasyonları içerisine BHE, Turner sendromu (TS), kronik böbrek yetmezliği (KBY), Prader-Willi sendromu (PWS), SHOX geni delesyonu veya mutasyonu, gestasyon yaşına göre düşük doğum ağırlıklı (SGA) ve boy kısalığı olan çocuklar ve idiopatik boy kısalıkları girmektedir. Pediatrik hastalar için birçok organizasyon tarafından büyüme hormonu tedavisinin başlanması kriterleri tanımlanmıştır. Biz bu yazıda pediatrik ve adölesan hastalarda büyüme hormonu tedavisi endikasyonlarını özetledik

🔖

Cite This Article

ŞİMŞEK, E., ŞİMŞEK, T. (2017). Growth Hormone Treatment Indications in Children and Adolescents. Osmangazi Tıp Dergisi, Cilt: 39 - Sayı: 3, 104–114. https://ajindex.com/articles/287838

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Wilson TA, Rose SR, Cohen P, et al; Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr, 2003;143(4), 415-421
  2. Davenport ML. Approach to the patient with Turner syndrome. J Clin Endocrinol Metab, 2010;95 (4), 1487-1495
  3. Rao E, Weiss B, Fukami M, et al. Pseudootosomal deletions encompassing a novel homebox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet, 1997;16 (1), 54-63
  4. Soucek O, Zapletalova J, Zemkova D, et al. Prepubertal girls with Turner syndrome and children with isolated SHOX deficiency have similar bone geometry at the Radius. J Clin Endocrinol Metab, 2013;98 (7), E1241-E1247
  5. Stephure DK; Canadian Growth Hormone Advisory Committee. Impact of growth hormone supplementation on adult height in turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab, 2005;90 (6), 3360-3366
  6. Ross JL, Quigley CA, Cao D, et al. Growth hormone plus childhood low-dose estrogen in Turner syndrome. N Eng J Med 2011;364 (13), 1230-1242
  7. Davenport ML, Crowe BJ, Travers SH, et al Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized controlled, multicenter trial. J Clin Endocrinol Metab, 2007;92(9), 3406-3416
  8. Linglart A, Cabrol S, Berlier P, et al; French Collaborative Young Turner Study Group. Growth hormone treatment before the age of 4 years prevents short stature in young girls with Turner syndrome. Eur J Endocrinol,2011; 164(6),891-897
  9. Bondy CA; Turner Syndrome Study Group Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab, 2007;92(1):10-25 10. Baxter I, Bryant J, Cave CB, Milne R. Recombinant growth hormon for children and adolescents with Turner syndrome. Cochrane Database Syst Rev, 2007;(1):CD003887
  10. Menke LA, Sas TC, de Muinck Keizer-Schrama SM, et al. Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome. J Clin Endocrinol Metab, 2010;95(3)1151–1160
  11. Gault EJ, Perry RJ, Cole TJ, et al; British Society for Paediatric Endocrinology and Diabetes. Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial. BMJ, 2011;342:d1980
  12. Quigley CA, Crowe BJ, An